Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
NACompletedINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
June 30, 2002
Primary Completion Date
August 31, 2004
Conditions
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
BIOLOGICAL
sargramostim
Trial Locations (1)
14263-0001
Roswell Park Cancer Institute, Buffalo
All Listed Sponsors
lead
Roswell Park Cancer Institute
OTHER
NCT00053157 - Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia | Biotech Hunter | Biotech Hunter